<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8AB7AD3B-7C13-4FB5-B0FB-A35009E21FB2"><gtr:id>8AB7AD3B-7C13-4FB5-B0FB-A35009E21FB2</gtr:id><gtr:firstName>Victor</gtr:firstName><gtr:otherNames>Leszek</gtr:otherNames><gtr:surname>Tybulewicz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/201636C4-A28A-45C9-B123-C1341019BBA0"><gtr:id>201636C4-A28A-45C9-B123-C1341019BBA0</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801110"><gtr:id>56E6CC91-E9E3-4A88-8178-792AEBE443F9</gtr:id><gtr:title>New mouse models for tackling motor neuron disease and other neurodegenerative disorders.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801110</gtr:grantReference><gtr:abstractText>This application is for a 4-year research project to create four new valuable mouse models in which to study neurodegeneration, with a long term view to finding therapeutics. These mouse strains complement and are different from existing models. During this award we will make the mice plus control strains, carry out initial ?clinical? analysis, and will make all the mice freely available to all other interested researchers.
 
Motor neuron diseases (MNDs) are relatively common (in UK 1 in 400 death certificates is issued for some form of MND) and can strike at any age ? spinal muscular atrophy is the biggest single genetic killer of children world-wide, whereas amyotrophic lateral sclerosis (ALS) is a disease of mid-life that has a lifetime risk of up to 1 in 600. These diseases progress inexorably to paralysis and death and we have no treatments that improve quality of life or lifespan of sufferers. MNDs have a genetic component but for ALS only one major effect causative gene, SOD1 has been found (in 1993) and we still have no idea why the mutant form of the protein kills neurons. Recently a protein called TDP43 was identified which aggregates abnormally in the nerve cells of people suffering from ALS and in 2008 rare families have been identified who succumb to ALS with death in mid-life, because they have mutations in the TDP43 gene. TDP43 protein abnormalities have also been found in frontotemporal dementia (the most common form of dementia after Alzheimer?s disease), and Parkinson?s disease, Pick?s disease and other forms of neurodegeneration.

Once a human mutant gene such as SOD1 or TDP43 has been identified, the next step is to genetically alter mice so that they recapitulate the human disease and we can study the pathological processes leading to illness and death. SOD1 transgenic mice have been tremendously helpful in understanding ALS, but have disadvantages. Currently no TDP43 mouse models exist. We want to create two new strains of mice, using newer technologies, which more closely model ALS in humans. These mice will be better for understanding human disease, for finding early ?biomarkers? of disease, and for trialling new therapies because they more closely replicate what is happening in humans. We will make the mice freely available to all researchers, without ties, by distributing them in the major mutant mouse repositories in Europe and USA for sending out to all research labs.</gtr:abstractText><gtr:technicalSummary>Amyotrophic lateral sclerosis (ALS) is mostly (~80%) sporadic but familial forms (FALS, ~20%) are known. The SOD1 gene is the most common causative gene for FALS, and recently rare mutations have been identified in the TDP43 gene. This is of interest because TDP43 is the major ubiquitinated protein in inclusions in both sporadic and familial ALS ? although not SOD1 related ALS.

We are requesting funding for one postdoc and one technician (minimum staffing to make this application realistic) to create two novel mouse strains modelling amyotrophic lateral sclerosis (ALS) with the SOD1 human genomic coding region knocked in, and two novel strains with a human TDP43 cDNA knocked in. These mouse strains are essential for understanding ALS because: if the knock in mice have a mid-life disease, this would arise from mutation, not from overexpression of the transgene array, which is known to have an effect in existing SOD1 transgenics; the model is physiologically more relevant than existing transgenics, giving us a better understanding of pathology and a better model for conventional and gene therapeutics ? including siRNA and lentiviruses; this model also gives us a better knowledge of the protein interactions that occur in ALS because it is biochemically more relevant to the human disease; this model helps address the biophysics/biochemistry of mutant:wildtype dimers and enzyme function, in a variety of primary cell lines, including embryonic stem cells and motor neurons; a mouse with late onset disease will direct us to biomarkers, desperately needed by ALS clinicians. Critically, we will make Cre-conditional knock in mice in which the mutation can be turned off in any tissues ? thus informing us, for example, about motor neuron ? glia interactions as we already know SOD1 induced motor neuron death is not cell autonomous and therefore glia and other cells may be targets for therapy. We wish to make knock in mice for both mutant SOD1 and TDP43, because although mutations in these genes may feed into a final common pathway, the lack of TDP43 pathology in SOD1 mutant ALS clearly shows the genes have different initial effects. 

A critical feature of this award is that we will make the mice freely available immediately, via the European Mutant Mouse Archive and the Jackson Laboratory, for distribution to all interested laboratories.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>951818</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>NIMR and mouse engineering</gtr:description><gtr:id>A1E62858-74DB-4C12-BF87-A1AE98AB72F4</gtr:id><gtr:impact>grant and papers</gtr:impact><gtr:partnerContribution>expertise in manipulating ES cells.</gtr:partnerContribution><gtr:piContribution>a postdoc, grant funding, expertise.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Private meeting with major funders</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B05EB94A-3786-4F33-B193-75C5AA832F7A</gtr:id><gtr:impact>Private meeting to inform major funders of research in motor neuron disease supported by the charity in question.

Maintaining funders enthusiasm and interest and showing value for money.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>Pre-2006,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit by fundraisers from MNDA</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>968420F8-A487-44FC-B48A-FA0E6355807F</gtr:id><gtr:impact>Fundraisers from MNDA visited to learn more of current research. These people are well-informed on issues regarding MND and care for people with MND, but are not scientists and do not necessarily have easy access to researchers.

Better informed fundraisers.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open day for patients</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5BFDFEEB-3D5D-4CB8-944E-7929E96F512A</gtr:id><gtr:impact>Talking directly to patients and carers about animal research and how we work with animals to understand motor neuron disease.

Telling patients about the current state of our work.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genetic engineering workshop on humanisation</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1BEDAD32-0196-4579-AC94-3DFCAF29C72F</gtr:id><gtr:impact>High level workshop for 30 international researchers to discuss issues on humanisation of the mouse genome.

Collaborations and networking of expertise</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>994155</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (Fus humanised)</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L021056/1</gtr:fundingRef><gtr:id>4A215498-95DB-44B7-A6C5-C11958B5FEE9</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>ALSA project grant</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>ALS Association</gtr:fundingOrg><gtr:fundingRef>Fisher 15-IIP-198</gtr:fundingRef><gtr:id>C1289618-E5B6-483D-99CF-5E295FCAFDD4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88690</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship MNDA Humanizing the Tardbp (TDP43) locus in the mouse</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>Fisher (10/442)</gtr:fundingRef><gtr:id>A2DAFA15-35BA-46E1-9DA5-1448A3348166</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9601</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosetrees award</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>29685C41-9F1A-4BDC-AF67-34CA3FA7D863</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112690</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Motor Neurone Disease Association PhD studentship (Fus)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>F5245179-13ED-4115-BCB7-AA134F284C9F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Acad Med Sci humanisation of animals - giving evidence</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8B6E5B8E-8D16-44BE-9AFB-D90D426BD692</gtr:id><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Mouse cell line that we may analyse rather than working with whole animals, thus helps with aims of NC3Rs.</gtr:description><gtr:id>B42FDAB0-9023-4BF3-9DA2-45E5B6B9961E</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Engineered mouse FUS humanised ES cells.</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Humanised genomic wildtype FUS gene in mouse</gtr:description><gtr:id>C3B6C7B0-545D-4A4D-8B1D-A3A2166D09BA</gtr:id><gtr:impact>Pending</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mouse humanised wildtype FUS model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Engineered mouse embryonic stem cell with knocked in human FUS gene - wildtype and mutant</gtr:description><gtr:id>3E8399F7-08A3-4E1B-94E5-EB3B55651C58</gtr:id><gtr:impact>Research on these cell lines only just beginning.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>mouse cells with humanised FUS wt and mutant</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Manipulated mouse embryonic stem cells to model aspects of Down syndrome</gtr:description><gtr:id>25C6017C-02FA-4D7E-91AE-62DB472FECCB</gtr:id><gtr:impact>academic papers</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mouse embryonic stem cells for Down syndrome</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse with endogenous mutation in ALS gene (Sod1 D83G)</gtr:description><gtr:id>C87E5CB0-696F-4CF8-B723-285571E583FF</gtr:id><gtr:impact>Paper submitted currently, after which the mouse will be made freely available. 
Second paper being written.
We anticipate this mouse will be of interest to the ALS research community.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mouse model Sod1 D83G</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Novel antibody that detects mutant FUS only, including in our genome engineered mouse.</gtr:description><gtr:id>B1FFDA49-9FC7-4733-BBD3-B61B247155F4</gtr:id><gtr:impact>Mice/antibody used currently by collaborators e.g. Fratta/Ule/Schiavo. Will make freely available after our first
publication.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A new antibody - mouse system for analysing FUS ALS, the Delta14 FUS mouse</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse models of motor neuron degeneration, with a specific mutation in the gene FUS (delta 14)</gtr:description><gtr:id>23EB2055-D773-417B-A9AB-C47B4C1852E1</gtr:id><gtr:impact>Papers pending, and model is basis of two new grant applications (both successful)</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mouse models for fus mnd delta 14 only</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3641D747-8A3B-4AB6-A737-2452292A5A0D"><gtr:id>3641D747-8A3B-4AB6-A737-2452292A5A0D</gtr:id><gtr:title>SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes.</gtr:title><gtr:parentPublicationTitle>The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b43d32f2b6cfef312c3c6a528071c8e6"><gtr:id>b43d32f2b6cfef312c3c6a528071c8e6</gtr:id><gtr:otherNames>Bunton-Stasyshyn RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-8584</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/46C4318F-7E20-46AE-A7A0-F7FA16AC36EB"><gtr:id>46C4318F-7E20-46AE-A7A0-F7FA16AC36EB</gtr:id><gtr:title>A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/311b04aa4c17b316103c9775174f68e9"><gtr:id>311b04aa4c17b316103c9775174f68e9</gtr:id><gtr:otherNames>Ricketts T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5887B02D-B962-453C-9793-104CAF0529A3"><gtr:id>5887B02D-B962-453C-9793-104CAF0529A3</gtr:id><gtr:title>Is SOD1 loss of function involved in amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/03fd54e97f8d443160f933229c72f332"><gtr:id>03fd54e97f8d443160f933229c72f332</gtr:id><gtr:otherNames>Saccon RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1FC503D6-DDCC-47A9-8B96-9452595A84F3"><gtr:id>1FC503D6-DDCC-47A9-8B96-9452595A84F3</gtr:id><gtr:title>SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments.</gtr:title><gtr:parentPublicationTitle>Mammalian genome : official journal of the International Mammalian Genome Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0938-8990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6385032E-44C5-42D0-85F1-2A0E041C76A4"><gtr:id>6385032E-44C5-42D0-85F1-2A0E041C76A4</gtr:id><gtr:title>An unusual presentation for SOD1-ALS: isolated facial diplegia.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D99E1051-D91E-40DB-9578-9CE675A80733"><gtr:id>D99E1051-D91E-40DB-9578-9CE675A80733</gtr:id><gtr:title>A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/311b04aa4c17b316103c9775174f68e9"><gtr:id>311b04aa4c17b316103c9775174f68e9</gtr:id><gtr:otherNames>Ricketts T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B70488DD-9F21-4070-B18A-D1E676380652"><gtr:id>B70488DD-9F21-4070-B18A-D1E676380652</gtr:id><gtr:title>A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d0c58f3e65f2f0c33dd5d66cc31fb81"><gtr:id>7d0c58f3e65f2f0c33dd5d66cc31fb81</gtr:id><gtr:otherNames>Acevedo-Arozena A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7E3179E-FFF1-4379-93A9-532C799B8678"><gtr:id>D7E3179E-FFF1-4379-93A9-532C799B8678</gtr:id><gtr:title>Rodent models of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52d08fa06edfabbc102dfeef4a0e4f35"><gtr:id>52d08fa06edfabbc102dfeef4a0e4f35</gtr:id><gtr:otherNames>McGoldrick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11A68F84-6885-42AE-90D5-95E2B01A6266"><gtr:id>11A68F84-6885-42AE-90D5-95E2B01A6266</gtr:id><gtr:title>Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB5EF914-2A5E-404D-AEBD-FEFA87B6AA6C"><gtr:id>CB5EF914-2A5E-404D-AEBD-FEFA87B6AA6C</gtr:id><gtr:title>Rodent models of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52d08fa06edfabbc102dfeef4a0e4f35"><gtr:id>52d08fa06edfabbc102dfeef4a0e4f35</gtr:id><gtr:otherNames>McGoldrick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9300EFA5-44C5-44F3-8108-DC18FD76BD56"><gtr:id>9300EFA5-44C5-44F3-8108-DC18FD76BD56</gtr:id><gtr:title>Profilin1 E117G is a moderate risk factor for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A642B97-586B-4C3F-8E0F-2E2C65CD689B"><gtr:id>3A642B97-586B-4C3F-8E0F-2E2C65CD689B</gtr:id><gtr:title>Genomically humanized mice: technologies and promises.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c5f2caa31f81dc3dd97e3cb514bba47"><gtr:id>4c5f2caa31f81dc3dd97e3cb514bba47</gtr:id><gtr:otherNames>Devoy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-0056</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801110</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>